The future of IBD treatment

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Throughout most of the past 50 years, treatment of Crohn's disease and ulcerative colitis has been dominated by the use of agents whose efficacy was defined on an empiric basis. Many of these, including most especially 5-amino salicylic acid (5-ASA)-based agents and corticosteroids, remain mainstays of current treatment even as research is catching up with clinical experience to define the mechanistic basis of their efficacy. Other agents, also of established utility in at least a subset of patients, were developed on the basis of general inferences about disease pathogenesis. These agents are exemplified by antibiotics (metronidazole) and immunosuppressive agents (azathioprine/6-mercaptopurine, methotrexate, and cyclosporine); attention was directed on the assumption of the general likely importance of microbial species and immunoactivation, respectively. However, the rapid progress, even if still incomplete in understanding of pathophysiological mechanisms that play a role in IBD, has transformed the development of new therapeutic agents, enabling the development of several agents now available or currently in advanced clinical development. It is notable that each of the major overall thrusts in development of new therapeutic strategies parallels, and may be reasonably viewed as the partial outgrowth of, dominant areas of progress in understanding of disease mechanisms relevant to IBD.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalJournal of Gastroenterology
Volume38
Issue numberSUPPL. 15
StatePublished - 2003

Fingerprint

6-Mercaptopurine
Salicylic Acid
Metronidazole
Azathioprine
Therapeutics
Immunosuppressive Agents
Ulcerative Colitis
Methotrexate
Crohn Disease
Cyclosporine
Adrenal Cortex Hormones
Anti-Bacterial Agents
Research

Keywords

  • Inflammatory bowel disease
  • Microbial flora
  • Mucosal immunology

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The future of IBD treatment. / Podolsky, Daniel K.

In: Journal of Gastroenterology, Vol. 38, No. SUPPL. 15, 2003, p. 63-66.

Research output: Contribution to journalArticle

Podolsky, DK 2003, 'The future of IBD treatment', Journal of Gastroenterology, vol. 38, no. SUPPL. 15, pp. 63-66.
Podolsky, Daniel K. / The future of IBD treatment. In: Journal of Gastroenterology. 2003 ; Vol. 38, No. SUPPL. 15. pp. 63-66.
@article{01ca6764a7d74d10a45fc54b8c1a626c,
title = "The future of IBD treatment",
abstract = "Throughout most of the past 50 years, treatment of Crohn's disease and ulcerative colitis has been dominated by the use of agents whose efficacy was defined on an empiric basis. Many of these, including most especially 5-amino salicylic acid (5-ASA)-based agents and corticosteroids, remain mainstays of current treatment even as research is catching up with clinical experience to define the mechanistic basis of their efficacy. Other agents, also of established utility in at least a subset of patients, were developed on the basis of general inferences about disease pathogenesis. These agents are exemplified by antibiotics (metronidazole) and immunosuppressive agents (azathioprine/6-mercaptopurine, methotrexate, and cyclosporine); attention was directed on the assumption of the general likely importance of microbial species and immunoactivation, respectively. However, the rapid progress, even if still incomplete in understanding of pathophysiological mechanisms that play a role in IBD, has transformed the development of new therapeutic agents, enabling the development of several agents now available or currently in advanced clinical development. It is notable that each of the major overall thrusts in development of new therapeutic strategies parallels, and may be reasonably viewed as the partial outgrowth of, dominant areas of progress in understanding of disease mechanisms relevant to IBD.",
keywords = "Inflammatory bowel disease, Microbial flora, Mucosal immunology",
author = "Podolsky, {Daniel K.}",
year = "2003",
language = "English (US)",
volume = "38",
pages = "63--66",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "SUPPL. 15",

}

TY - JOUR

T1 - The future of IBD treatment

AU - Podolsky, Daniel K.

PY - 2003

Y1 - 2003

N2 - Throughout most of the past 50 years, treatment of Crohn's disease and ulcerative colitis has been dominated by the use of agents whose efficacy was defined on an empiric basis. Many of these, including most especially 5-amino salicylic acid (5-ASA)-based agents and corticosteroids, remain mainstays of current treatment even as research is catching up with clinical experience to define the mechanistic basis of their efficacy. Other agents, also of established utility in at least a subset of patients, were developed on the basis of general inferences about disease pathogenesis. These agents are exemplified by antibiotics (metronidazole) and immunosuppressive agents (azathioprine/6-mercaptopurine, methotrexate, and cyclosporine); attention was directed on the assumption of the general likely importance of microbial species and immunoactivation, respectively. However, the rapid progress, even if still incomplete in understanding of pathophysiological mechanisms that play a role in IBD, has transformed the development of new therapeutic agents, enabling the development of several agents now available or currently in advanced clinical development. It is notable that each of the major overall thrusts in development of new therapeutic strategies parallels, and may be reasonably viewed as the partial outgrowth of, dominant areas of progress in understanding of disease mechanisms relevant to IBD.

AB - Throughout most of the past 50 years, treatment of Crohn's disease and ulcerative colitis has been dominated by the use of agents whose efficacy was defined on an empiric basis. Many of these, including most especially 5-amino salicylic acid (5-ASA)-based agents and corticosteroids, remain mainstays of current treatment even as research is catching up with clinical experience to define the mechanistic basis of their efficacy. Other agents, also of established utility in at least a subset of patients, were developed on the basis of general inferences about disease pathogenesis. These agents are exemplified by antibiotics (metronidazole) and immunosuppressive agents (azathioprine/6-mercaptopurine, methotrexate, and cyclosporine); attention was directed on the assumption of the general likely importance of microbial species and immunoactivation, respectively. However, the rapid progress, even if still incomplete in understanding of pathophysiological mechanisms that play a role in IBD, has transformed the development of new therapeutic agents, enabling the development of several agents now available or currently in advanced clinical development. It is notable that each of the major overall thrusts in development of new therapeutic strategies parallels, and may be reasonably viewed as the partial outgrowth of, dominant areas of progress in understanding of disease mechanisms relevant to IBD.

KW - Inflammatory bowel disease

KW - Microbial flora

KW - Mucosal immunology

UR - http://www.scopus.com/inward/record.url?scp=0037256182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037256182&partnerID=8YFLogxK

M3 - Article

C2 - 12698875

AN - SCOPUS:0037256182

VL - 38

SP - 63

EP - 66

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - SUPPL. 15

ER -